Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30218031 | 0.82 | NPSR1 (0.39) | NPSR1FLT3ADORA3NPC1ALDH1A1 | |
| SCHEMBL20019155 | 0.74 | NPSR1 (0.50) | NPSR1FLT3ADORA3NPC1ALDH1A1 | |
| SCHEMBL3313454 | 0.74 | MIF (0.53) | NPSR1FLT3ADORA3NPC1ALDH1A1 | |
| SCHEMBL10238 | 0.74 | NPSR1 (0.50) | NPSR1FLT3ADORA3NPC1ALDH1A1 | |
| SCHEMBL84864 | 0.74 | NPSR1 (0.50) | NPSR1FLT3ADORA3NPC1ALDH1A1 | |
| SCHEMBL23132987 | 0.74 | NPSR1 (0.53) | NPSR1FLT3ADORA3NPC1ALDH1A1 | |
| SCHEMBL335455 | 0.74 | PKM (0.51) | NPSR1FLT3ADORA3NPC1ALDH1A1 | |
| SCHEMBL13325708 | 0.74 | NPC1 (0.50) | NPSR1FLT3ADORA3NPC1ALDH1A1 | |
| SCHEMBL729145 | 0.74 | NPSR1 (0.50) | NPSR1FLT3ADORA3NPC1ALDH1A1 | |
| SCHEMBL19748929 | 0.74 | FLT3 (0.58) | NPSR1FLT3ADORA3NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442947-B1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | EPIZYME INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3442947-B1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | EPIZYME INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11566022-B2 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-01-31 | — | — | US | disclosed |
| US-20220402904-A1 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | NOVARTIS AG (CH) | 2022-12-22 | — | — | US | disclosed |
| US-20220185822-A1 | SELECTIVE LIGANDS OF HUMAN CONSTITUTIVE ANDROSTANE RECEPTOR | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2022-06-16 | — | — | US | disclosed |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11053260-B2 | Tri-cycle compound and applications thereof | FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) | 2021-07-06 | — | — | US | disclosed |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2021-07-01 | — | — | US | disclosed |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2021-07-01 | — | — | US | disclosed |
| CN-109897033-B | Method for synthesizing iodine-containing imidazo [1, 2a ] pyridine compound | 浙江工业大学上虞研究院有限公司 | 2021-06-11 | — | — | CN | disclosed |
| EP-2094712-A2 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | Vertex Pharmceuticals Incorporated (US) | 2009-09-02 | — | — | EP | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| WO-2008060597-A2 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080103136-A1 | Novel Fused Imidazole Derivative | MSD K.K. (JP) | 2008-05-01 | — | — | US | disclosed |
| US-20080090860-A1 | Retinoid x receptor modulators | GARDINIER KEVIN M | 2008-04-17 | — | — | US | disclosed |
| US-20080090860-A1 | Retinoid x receptor modulators | GARDINIER KEVIN M | 2008-04-17 | — | — | US | disclosed |
| US-7348359-B2 | Retinoid X receptor modulators | ELI LILLY AND COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20070219205-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-20 | — | — | US | disclosed |
| EP-1813613-A1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566022-B2 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | HBZ, ZFX, HBG1 | NPSR1 4663/4885FLT3 2923/4885ADORA3 3805/4885 |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | NPSR1 4128/4885FLT3 1824/4885ADORA3 1079/4885 |
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | NPSR1 25/4885FLT3 688/4885ADORA3 123/4885 |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | NPSR1 341/4885FLT3 640/4885ADORA3 474/4885 |
| US-20080090860-A1 | Retinoid x receptor modulators | RXRA, RXRG, RXRB | NPSR1 185/4885FLT3 1340/4885ADORA3 206/4885 |
| US-20220402904-A1 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | HBZ, ZFX, HBG1 | NPSR1 4631/4885FLT3 2770/4885ADORA3 3598/4885 |
| US-20070219205-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | MAP3K20, ABL1, MAP3K5 | NPSR1 4375/4885FLT3 382/4885ADORA3 3493/4885 |
| US-11053260-B2 | Tri-cycle compound and applications thereof | SLC10A1, NR1H4, HAVCR2 | NPSR1 3790/4885FLT3 649/4885ADORA3 3616/4885 |
| US-20080103136-A1 | Novel Fused Imidazole Derivative | HRH4, H1-4, H1-3 | NPSR1 192/4885FLT3 58/4885ADORA3 137/4885 |
| US-20220185822-A1 | SELECTIVE LIGANDS OF HUMAN CONSTITUTIVE ANDROSTANE RECEPTOR | NR1I2, NR1H2, NR1H4 | NPSR1 282/4885FLT3 2825/4885ADORA3 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.